Literature DB >> 8666067

Non-replicating expression vectors: applications in vaccine development and gene therapy.

K J Limbach1, E Paoletti.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8666067      PMCID： PMC2271436          DOI： 10.1017/s0950268800052547

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN： 0950-2688            Impact factor:   2.451


× No keyword cloud information.
  76 in total

1.  Isogenic adenoviruses type 5 expressing or not expressing the E1A gene: efficiency as virus vectors in the vaccination of permissive and non-permissive species.

Authors:  M Eloit; M Adam
Journal:  J Gen Virol       Date:  1995-07       Impact factor: 3.891

2.  NYVAC: a highly attenuated strain of vaccinia virus.

Authors:  J Tartaglia; M E Perkus; J Taylor; E K Norton; J C Audonnet; W I Cox; S W Davis; J van der Hoeven; B Meignier; M Riviere
Journal:  Virology       Date:  1992-05       Impact factor: 3.616

3.  A controlled study of adenoviral-vector-mediated gene transfer in the nasal epithelium of patients with cystic fibrosis.

Authors:  M R Knowles; K W Hohneker; Z Zhou; J C Olsen; T L Noah; P C Hu; M W Leigh; J F Engelhardt; L J Edwards; K R Jones
Journal:  N Engl J Med       Date:  1995-09-28       Impact factor: 91.245

4.  A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/LAI). The AGIS Group, and l'Agence Nationale de Recherche sur le SIDA.

Authors:  G Pialoux; J L Excler; Y Rivière; G Gonzalez-Canali; V Feuillie; P Coulaud; J C Gluckman; T J Matthews; B Meignier; M P Kieny
Journal:  AIDS Res Hum Retroviruses       Date:  1995-03       Impact factor: 2.205

5.  Efficient in vivo transduction of the neonatal mouse liver with pseudotyped retroviral vectors.

Authors:  A Miyanohara; J K Yee; K Bouic; P LaPorte; T Friedmann
Journal:  Gene Ther       Date:  1995-03       Impact factor: 5.250

6.  T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years.

Authors:  R M Blaese; K W Culver; A D Miller; C S Carter; T Fleisher; M Clerici; G Shearer; L Chang; Y Chiang; P Tolstoshev; J J Greenblatt; S A Rosenberg; H Klein; M Berger; C A Mullen; W J Ramsey; L Muul; R A Morgan; W F Anderson
Journal:  Science       Date:  1995-10-20       Impact factor: 47.728

7.  Cytokine gene therapy with interleukin-2-transduced fibroblasts: effects of IL-2 dose on anti-tumor immunity.

Authors:  H Fakhrai; D L Shawler; R Gjerset; R K Naviaux; J Koziol; I Royston; R E Sobol
Journal:  Hum Gene Ther       Date:  1995-05       Impact factor: 5.695

8.  Induction of human immunodeficiency virus type 1 (HIV-1)-specific cytolytic T lymphocyte responses in seronegative adults by a nonreplicating, host-range-restricted canarypox vector (ALVAC) carrying the HIV-1MN env gene.

Authors:  M A Egan; W A Pavlat; J Tartaglia; E Paoletti; K J Weinhold; M L Clements; R F Siliciano
Journal:  J Infect Dis       Date:  1995-06       Impact factor: 5.226

9.  Protection of mice and swine from pseudorabies virus conferred by vaccinia virus-based recombinants.

Authors:  M Riviere; J Tartaglia; M E Perkus; E K Norton; C M Bongermino; F Lacoste; C Duret; P Desmettre; E Paoletti
Journal:  J Virol       Date:  1992-06       Impact factor: 5.103

10.  The safety and use of canarypox vectored vaccines.

Authors:  S A Plotkin; M Cadoz; B Meignier; C Méric; O Leroy; J L Excler; J Tartaglia; E Paoletti; E Gonczol; G Chappuis
Journal:  Dev Biol Stand       Date:  1995
View more
  8 in total

Review 1.  Synthetic DNA vaccine strategies against persistent viral infections.

Authors:  Daniel O Villarreal; Kendra T Talbott; Daniel K Choo; Devon J Shedlock; David B Weiner
Journal:  Expert Rev Vaccines       Date:  2013-05       Impact factor: 5.217

2.  The Jenner bicentenary; still uses for smallpox vaccine.

Authors:  D Baxby
Journal:  Epidemiol Infect       Date:  1996-06       Impact factor: 2.451

3.  The 131-amino-acid repeat region of the essential 39-kilodalton core protein of fowlpox virus FP9, equivalent to vaccinia virus A4L protein, is nonessential and highly immunogenic.

Authors:  D Boulanger; P Green; T Smith; C P Czerny; M A Skinner
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103

4.  Identification and characterization of three immunodominant structural proteins of fowlpox virus.

Authors:  Denise Boulanger; Philip Green; Brenda Jones; Gwenn Henriquet; Lawrence G Hunt; Stephen M Laidlaw; Paul Monaghan; Michael A Skinner
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

5.  Characterization of avipoxviruses from wild birds in Norway.

Authors:  Simon Chioma Weli; Malachy Ifeanyi Okeke; Morten Tryland; Oivind Nilssen; Terje Traavik
Journal:  Can J Vet Res       Date:  2004-04       Impact factor: 1.310

6.  Engagement of monocytes, NK cells, and CD4+ Th1 cells by ALVAC-SIV vaccination results in a decreased risk of SIVmac251 vaginal acquisition.

Authors:  Giacomo Gorini; Slim Fourati; Monica Vaccari; Mohammad Arif Rahman; Shari N Gordon; Dallas R Brown; Lynn Law; Jean Chang; Richard Green; Fredrik Barrenäs; Namal P M Liyanage; Melvin N Doster; Luca Schifanella; Massimiliano Bissa; Isabela Silva de Castro; Robyn Washington-Parks; Veronica Galli; Deborah H Fuller; Sampa Santra; Michael Agy; Ranajit Pal; Robert E Palermo; Georgia D Tomaras; Xiaoying Shen; Celia C LaBranche; David C Montefiori; David J Venzon; Hung V Trinh; Mangala Rao; Michael Gale; Rafick P Sekaly; Genoveffa Franchini
Journal:  PLoS Pathog       Date:  2020-03-12       Impact factor: 6.823

Review 7.  COVID-19 Vaccines: An Overview of Different Platforms.

Authors:  Dmitry Kudlay; Andrey Svistunov
Journal:  Bioengineering (Basel)       Date:  2022-02-12

Review 8.  Immunoprophylaxis against important virus disease of horses, farm animals and birds.

Authors:  J R Patel; J G M Heldens
Journal:  Vaccine       Date:  2009-03-13       Impact factor: 3.641
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.